Drugs / MSB11456
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03282851 | Nov 2017 → Oct 2019 | — | Fresenius Kabi SwissBioSim GmbH | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04512001 | Aug 2020 → Aug 2021 | rheumatoid arthritis | Fresenius Kabi SwissBioSim GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSB11456 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03282851 ↗ |
| Route | Other | “Subjects will receive a single injection of MSB11456 on Day 1.” NCT03282851 ↗ |